| Literature DB >> 35115906 |
Peizhen Peng1, Yang Song2, Lu Yang3, Haikun Wei1.
Abstract
Epileptic seizure prediction is one of the most used therapeutic adjuvant strategies for drug-resistant epilepsy. Conventional approaches commonly collect training and testing samples from the same patient due to inter-individual variability. However, the challenging problem of domain shift between various subjects remains unsolved, resulting in a low conversion rate to the clinic. In this work, a domain adaptation (DA)-based model is proposed to circumvent this issue. The short-time Fourier transform (STFT) is employed to extract the time-frequency features from raw EEG data, and an autoencoder is developed to map these features into high-dimensional space. By minimizing the inter-domain distance in the embedding space, this model learns the domain-invariant information, such that the generalization ability is improved by distribution alignment. Besides, to increase the feasibility of its application, this work mimics the data distribution under the clinical sampling situation and tests the model under this condition, which is the first study that adopts the assessment strategy. Experimental results on both intracranial and scalp EEG databases demonstrate that this method can minimize the domain gap effectively compared with previous approaches.Entities:
Keywords: EEG; STFT; domain adaptation; feature extraction; neuropsychiatric disorders; seizure prediction
Year: 2022 PMID: 35115906 PMCID: PMC8805457 DOI: 10.3389/fnins.2021.825434
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Figure 1Definition of three brain states in continuous epileptic EEG recordings.
Figure 2Seizure prediction is a patient-specific problem. The discriminative models (dashed line) of various individuals (circle and triangle) differ significantly.
Details of the Freiburg Hospital test set.
|
|
|
|
|
|
|---|---|---|---|---|
| Pt 1 | F | 15 | SP | 4 |
| Pt 2 | M | 38 | SP, CP, GTC | 3 |
| Pt 3 | M | 14 | SP, CP | 5 |
| Pt 4 | F | 26 | SP, CP, GTC | 5 |
| Pt 5 | F | 16 | SP, CP, GTC | 5 |
| Pt 6 | F | 31 | CP, GTC | 3 |
| Pt 8 | F | 32 | SP, CP | 2 |
| Pt 9 | M | 44 | CP, GTC | 4 |
| Pt 10 | M | 47 | SP, CP, GTC | 5 |
| Pt 11 | F | 10 | SP, CP, GTC | 4 |
| Pt 12 | F | 42 | SP, CP, GTC | 3 |
| Pt 13 | F | 22 | SP, CP, GTC | 2 |
| Pt 14 | F | 41 | CP, GTC | 4 |
| Pt 15 | M | 31 | SP, CP, GTC | 4 |
| Pt 16 | F | 50 | SP, CP, GTC | 5 |
| Pt 17 | M | 28 | SP, CP, GTC | 5 |
| Pt 18 | F | 25 | SP, CP | 5 |
| Pt 19 | F | 28 | SP, CP, GTC | 4 |
| Pt 20 | M | 33 | SP, CP, GTC | 5 |
| Pt 21 | M | 13 | SP, CP | 5 |
F, Female; M, Male; SP, simple partial; CP, complex partial; GTC, generalized tonic-clonic.
Details of the CHB-MIT test set.
|
|
|
|
|
|
|---|---|---|---|---|
| Pt 1 | F | 11 | SP, CP | 7 |
| Pt 2 | M | 11 | SP, CP, GTC | 3 |
| Pt 3 | F | 14 | SP, CP | 6 |
| Pt 5 | F | 7 | CP, GTC | 5 |
| Pt 6 | F | 2 | CP, GTC | 4 |
| Pt 7 | F | 15 | SP, CP, GTC | 3 |
| Pt 8 | M | 4 | SP, CP, GTC | 5 |
| Pt 9 | F | 10 | CP, GTC | 4 |
| Pt 10 | M | 3 | SP, CP, GTC | 6 |
| Pt 13 | F | 3 | SP, CP, GTC | 5 |
| Pt 14 | F | 9 | CP, GTC | 5 |
| Pt 17 | F | 12 | SP, CP, GTC | 3 |
| Pt 18 | F | 18 | SP, CP | 6 |
| Pt 19 | F | 19 | SP, CP, GTC | 3 |
| Pt 20 | F | 6 | SP, CP, GTC | 5 |
| Pt 21 | F | 13 | SP, CP | 4 |
F, Female; M, Male; SP, simple partial; CP, complex partial; GTC, generalized tonic-clonic.
Figure 3Illustration of clinical situation simulation.
Figure 4Block diagram of our model: the STFT module converts raw EEG recordings into time-frequency images to meet the input requirement of the AAE module. The AAE module maps each domain's data into a high-dimensional space. MMD loss is employed as the measure to align distributions of different domains. The Laplace prior is exploited to optimize the hidden code z using adversarial learning.
Results compared with conventional methods on the Freiburg Hospital database.
|
|
|
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| ||
| S.C. | Pt 1 | 0.64 | 0.21 | 0.66 | 0.20 | 0.69 | 0.19 | 0.70 | 0.17 | 0.79 | 0.16 |
| S.C. | Pt 2 | 0.63 | 0.3 | 0.65 | 0.28 | 0.66 | 0.26 | 0.67 | 0.24 | 0.82 | 0.12 |
| S.C. | Pt 3 | 0.58 | 0.24 | 0.59 | 0.23 | 0.62 | 0.22 | 0.64 | 0.22 | 0.74 | 0.20 |
| S.C. | Pt 4 | 0.64 | 0.25 | 0.65 | 0.24 | 0.66 | 0.22 | 0.69 | 0.20 | 0.83 | 0.16 |
| S.C. | Pt 5 | 0.56 | 0.4 | 0.58 | 0.39 | 0.59 | 0.38 | 0.60 | 0.38 | 0.57 | 0.30 |
| S.C. | Pt 6 | 0.64 | 0.27 | 0.64 | 0.26 | 0.67 | 0.26 | 0.69 | 0.26 | 0.73 | 0.18 |
| S.C. | Pt 8 | 0.54 | 0.33 | 0.55 | 0.33 | 0.57 | 0.32 | 0.57 | 0.31 | 0.68 | 0.29 |
| S.C. | Pt 9 | 0.70 | 0.18 | 0.72 | 0.17 | 0.75 | 0.15 | 0.77 | 0.13 | 0.77 | 0.19 |
| S.C. | Pt 10 | 0.52 | 0.34 | 0.53 | 0.33 | 0.55 | 0.32 | 0.58 | 0.30 | 0.81 | 0.16 |
| S.C. | Pt 11 | 0.50 | 0.32 | 0.5 | 0.30 | 0.52 | 0.29 | 0.52 | 0.28 | 0.68 | 0.29 |
| S.C. | Pt 12 | 0.72 | 0.15 | 0.74 | 0.13 | 0.75 | 0.12 | 0.77 | 0.13 | 0.82 | 0.09 |
| S.C. | Pt 13 | 0.55 | 0.27 | 0.56 | 0.25 | 0.59 | 0.24 | 0.60 | 0.23 | 0.66 | 0.29 |
| S.C. | Pt 14 | 0.56 | 0.46 | 0.57 | 0.46 | 0.58 | 0.44 | 0.60 | 0.43 | 0.75 | 0.22 |
| S.C. | Pt 15 | 0.66 | 0.17 | 0.66 | 0.16 | 0.69 | 0.15 | 0.69 | 0.13 | 0.83 | 0.12 |
| S.C. | Pt 16 | 0.59 | 0.33 | 0.6 | 0.32 | 0.63 | 0.31 | 0.65 | 0.30 | 0.85 | 0.12 |
| S.C. | Pt 17 | 0.59 | 0.34 | 0.62 | 0.33 | 0.63 | 0.31 | 0.65 | 0.30 | 0.77 | 0.21 |
| S.C. | Pt 18 | 0.76 | 0.14 | 0.78 | 0.13 | 0.80 | 0.11 | 0.83 | 0.12 | 0.84 | 0.09 |
| S.C. | Pt 19 | 0.48 | 0.29 | 0.48 | 0.28 | 0.48 | 0.27 | 0.5 | 0.26 | 0.73 | 0.23 |
| S.C. | Pt 20 | 0.45 | 0.33 | 0.47 | 0.33 | 0.48 | 0.33 | 0.51 | 0.32 | 0.82 | 0.15 |
| S.C. | Pt 21 | 0.60 | 0.28 | 0.62 | 0.27 | 0.62 | 0.25 | 0.65 | 0.24 | 0.66 | 0.31 |
| Avg. | 0.59 | 0.28 | 0.61 | 0.27 | 0.63 | 0.26 | 0.64 | 0.25 | 0.76 | 0.19 | |
S.C., simulated clinical samples; S
uses NO samples of the predictor user.
Results compared with conventional methods on the CHB-MIT database.
|
|
|
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| ||
| S.C. | Pt 1 | 0.52 | 0.33 | 0.54 | 0.31 | 0.55 | 0.31 | 0.56 | 0.31 | 0.77 | 0.25 |
| S.C. | Pt 2 | 0.46 | 0.37 | 0.47 | 0.37 | 0.48 | 0.34 | 0.49 | 0.32 | 0.56 | 0.32 |
| S.C. | Pt 3 | 0.59 | 0.30 | 0.60 | 0.30 | 0.63 | 0.29 | 0.63 | 0.28 | 0.70 | 0.24 |
| S.C. | Pt 5 | 0.48 | 0.39 | 0.48 | 0.37 | 0.49 | 0.35 | 0.51 | 0.34 | 0.74 | 0.23 |
| S.C. | Pt 6 | 0.64 | 0.3 | 0.66 | 0.29 | 0.68 | 0.28 | 0.70 | 0.28 | 0.79 | 0.27 |
| S.C. | Pt 7 | 0.53 | 0.21 | 0.56 | 0.21 | 0.56 | 0.29 | 0.57 | 0.26 | 0.71 | 0.15 |
| S.C. | Pt 8 | 0.58 | 0.26 | 0.60 | 0.25 | 0.61 | 0.24 | 0.63 | 0.23 | 0.82 | 0.22 |
| S.C. | Pt 9 | 0.51 | 0.34 | 0.54 | 0.33 | 0.55 | 0.33 | 0.56 | 0.32 | 0.78 | 0.20 |
| S.C. | Pt 10 | 0.5 | 0.31 | 0.51 | 0.29 | 0.53 | 0.28 | 0.54 | 0.26 | 0.72 | 0.24 |
| S.C. | Pt 13 | 0.46 | 0.21 | 0.47 | 0.20 | 0.50 | 0.28 | 0.50 | 0.27 | 0.54 | 0.37 |
| S.C. | Pt 14 | 0.46 | 0.38 | 0.48 | 0.38 | 0.49 | 0.36 | 0.50 | 0.34 | 0.80 | 0.14 |
| S.C. | Pt 17 | 0.42 | 0.37 | 0.43 | 0.35 | 0.44 | 0.35 | 0.44 | 0.35 | 0.75 | 0.3 |
| S.C. | Pt 18 | 0.49 | 0.29 | 0.52 | 0.29 | 0.53 | 0.27 | 0.54 | 0.25 | 0.70 | 0.22 |
| S.C. | Pt 19 | 0.56 | 0.28 | 0.58 | 0.27 | 0.60 | 0.25 | 0.63 | 0.23 | 0.73 | 0.19 |
| S.C. | Pt 20 | 0.57 | 0.24 | 0.59 | 0.22 | 0.60 | 0.2 | 0.62 | 0.28 | 0.82 | 0.16 |
| S.C. | Pt 21 | 0.63 | 0.25 | 0.66 | 0.24 | 0.67 | 0.22 | 0.70 | 0.20 | 0.68 | 0.28 |
| Avg. | 0.51 | 0.30 | 0.54 | 0.29 | 0.56 | 0.29 | 0.57 | 0.28 | 0.73 | 0.24 | |
S.C., simulated clinical samples; S.
Figure 5AUC of different seizure prediction models on the Freiburg Hospital test set (left) and the CHB-MIT test set (right).
Results compared with DA methods on the Freiburg Hospital database.
|
|
|
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| ||
| S.C. | Pt 1 | 0.57 | 0.22 | 0.62 | 0.21 | 0.78 | 0.19 | 0.83 | 0.18 | 0.79 | 0.16 |
| S.C. | Pt 2 | 0.56 | 0.28 | 0.60 | 0.26 | 0.73 | 0.26 | 0.82 | 0.25 | 0.82 | 0.12 |
| S.C. | Pt 3 | 0.52 | 0.23 | 0.62 | 0.22 | 0.77 | 0.22 | 0.78 | 0.20 | 0.74 | 0.2 |
| S.C. | Pt 4 | 0.49 | 0.23 | 0.60 | 0.23 | 0.61 | 0.21 | 0.62 | 0.20 | 0.83 | 0.16 |
| S.C. | Pt 5 | 0.57 | 0.37 | 0.53 | 0.35 | 0.78 | 0.35 | 0.79 | 0.33 | 0.57 | 0.30 |
| S.C. | Pt 6 | 0.53 | 0.23 | 0.60 | 0.23 | 0.63 | 0.23 | 0.70 | 0.23 | 0.73 | 0.18 |
| S.C. | Pt 8 | 0.45 | 0.33 | 0.51 | 0.33 | 0.53 | 0.33 | 0.55 | 0.30 | 0.68 | 0.29 |
| S.C. | Pt 9 | 0.49 | 0.37 | 0.51 | 0.36 | 0.68 | 0.26 | 0.70 | 0.24 | 0.77 | 0.19 |
| S.C. | Pt 10 | 0.52 | 0.33 | 0.54 | 0.32 | 0.62 | 0.32 | 0.64 | 0.31 | 0.81 | 0.16 |
| S.C. | Pt 11 | 0.59 | 0.33 | 0.57 | 0.32 | 0.67 | 0.30 | 0.79 | 0.31 | 0.68 | 0.29 |
| S.C. | Pt 12 | 0.59 | 0.36 | 0.63 | 0.34 | 0.73 | 0.24 | 0.75 | 0.22 | 0.82 | 0.09 |
| S.C. | Pt 13 | 0.45 | 0.29 | 0.56 | 0.29 | 0.69 | 0.27 | 0.69 | 0.26 | 0.66 | 0.29 |
| S.C. | Pt 14 | 0.45 | 0.46 | 0.52 | 0.45 | 0.65 | 0.44 | 0.60 | 0.44 | 0.75 | 0.22 |
| S.C. | Pt 15 | 0.56 | 0.16 | 0.67 | 0.16 | 0.52 | 0.36 | 0.74 | 0.16 | 0.83 | 0.12 |
| S.C. | Pt 16 | 0.44 | 0.35 | 0.48 | 0.33 | 0.76 | 0.33 | 0.64 | 0.31 | 0.85 | 0.12 |
| S.C. | Pt 17 | 0.44 | 0.36 | 0.47 | 0.35 | 0.53 | 0.32 | 0.52 | 0.32 | 0.77 | 0.21 |
| S.C. | Pt 18 | 0.58 | 0.36 | 0.61 | 0.35 | 0.77 | 0.22 | 0.77 | 0.21 | 0.84 | 0.09 |
| S.C. | Pt 19 | 0.45 | 0.29 | 0.47 | 0.28 | 0.53 | 0.27 | 0.58 | 0.26 | 0.73 | 0.23 |
| S.C. | Pt 20 | 0.47 | 0.34 | 0.53 | 0.34 | 0.62 | 0.31 | 0.66 | 0.31 | 0.82 | 0.15 |
| S.C. | Pt 21 | 0.52 | 0.30 | 0.54 | 0.29 | 0.52 | 0.27 | 0.66 | 0.26 | 0.66 | 0.31 |
| Avg. | 0.51 | 0.31 | 0.56 | 0.30 | 0.66 | 0.29 | 0.69 | 0.27 | 0.76 | 0.19 | |
S.C., simulated clinical samples; S.
Results compared with DA methods on the CHB-MIT database.
|
|
|
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| ||
| S.C. | Pt 1 | 0.55 | 0.34 | 0.61 | 0.33 | 0.74 | 0.30 | 0.74 | 0.28 | 0.77 | 0.25 |
| S.C. | Pt 2 | 0.43 | 0.38 | 0.49 | 0.38 | 0.66 | 0.37 | 0.64 | 0.35 | 0.56 | 0.32 |
| S.C. | Pt 3 | 0.51 | 0.28 | 0.50 | 0.27 | 0.65 | 0.25 | 0.67 | 0.24 | 0.70 | 0.24 |
| S.C. | Pt 5 | 0.48 | 0.42 | 0.51 | 0.40 | 0.69 | 0.37 | 0.69 | 0.36 | 0.74 | 0.23 |
| S.C. | Pt 6 | 0.46 | 0.29 | 0.52 | 0.27 | 0.72 | 0.27 | 0.72 | 0.25 | 0.79 | 0.27 |
| S.C. | Pt 7 | 0.54 | 0.25 | 0.56 | 0.24 | 0.73 | 0.21 | 0.73 | 0.19 | 0.71 | 0.15 |
| S.C. | Pt 8 | 0.48 | 0.27 | 0.60 | 0.26 | 0.67 | 0.25 | 0.66 | 0.24 | 0.82 | 0.22 |
| S.C. | Pt 9 | 0.46 | 0.31 | 0.51 | 0.29 | 0.58 | 0.27 | 0.57 | 0.25 | 0.78 | 0.20 |
| S.C. | Pt 10 | 0.45 | 0.28 | 0.46 | 0.27 | 0.52 | 0.25 | 0.52 | 0.24 | 0.72 | 0.24 |
| S.C. | Pt 13 | 0.48 | 0.21 | 0.51 | 0.39 | 0.61 | 0.38 | 0.62 | 0.26 | 0.54 | 0.37 |
| S.C. | Pt 14 | 0.47 | 0.39 | 0.48 | 0.39 | 0.64 | 0.36 | 0.65 | 0.35 | 0.80 | 0.14 |
| S.C. | Pt 17 | 0.49 | 0.38 | 0.50 | 0.37 | 0.61 | 0.37 | 0.59 | 0.35 | 0.75 | 0.30 |
| S.C. | Pt 18 | 0.50 | 0.30 | 0.49 | 0.30 | 0.57 | 0.28 | 0.61 | 0.28 | 0.70 | 0.22 |
| S.C. | Pt 19 | 0.51 | 0.39 | 0.51 | 0.36 | 0.62 | 0.34 | 0.62 | 0.24 | 0.73 | 0.19 |
| S.C. | Pt 20 | 0.53 | 0.25 | 0.55 | 0.23 | 0.70 | 0.23 | 0.66 | 0.21 | 0.82 | 0.16 |
| S.C. | Pt 21 | 0.50 | 0.27 | 0.52 | 0.26 | 0.63 | 0.24 | 0.68 | 0.22 | 0.68 | 0.28 |
| Avg. | 0.49 | 0.31 | 0.52 | 0.31 | 0.65 | 0.30 | 0.65 | 0.27 | 0.73 | 0.24 | |
S.C., simulated clinical samples.
Figure 6AUC of different DA models on the Freiburg Hospital test set (left) and the CHB-MIT test set (right).
Comparison results on the Freiburg Hospital database using various components.
|
|
|
|
|
|
|---|---|---|---|---|
| No | 0.60 ± 0.03 | 0.35 ± 0.03 | 0.63 ± 0.04 | 0.63 ± 0.03 |
| No | 0.67 ± 0.03 | 0.31 ± 0.03 | 0.68 ± 0.03 | 0.69 ± 0.03 |
| No | 0.71 ± 0.03 | 0.27 ± 0.03 | 0.72 ± 0.03 | 0.72 ± 0.03 |
| Our model | 0.76 ± 0.03 | 0.19 ± 0.03 | 0.78 ± 0.03 | 0.78 ± 0.03 |
S.
Comparison results on the CHB-MIT database using various components.
|
|
|
|
|
|
|---|---|---|---|---|
| No | 0.57 ± 0.03 | 0.36 ± 0.03 | 0.59 ± 0.03 | 0.59 ± 0.03 |
| No | 0.64 ± 0.04 | 0.33 ± 0.03 | 0.66 ± 0.04 | 0.66 ± 0.03 |
| No | 0.68 ± 0.03 | 0.29 ± 0.03 | 0.69 ± 0.03 | 0.70 ± 0.03 |
| Our model | 0.73 ± 0.03 | 0.24 ± 0.03 | 0.75 ± 0.03 | 0.75 ± 0.03 |
S.
Figure 7AUC of different inter-domain distance measures on the Freiburg Hospital test set and the CHB-MIT test set.